Pfizer (NYSE:PFE) received U.S. FDA Priority Review for a supplemental Biologics License Application covering PADCEV plus ...

What is Keytruda and how does it work? Experts explain the cancer immunotherapy as a global investigation raises concerns ...

Add Yahoo as a preferred source to see more of our stories on Google. Pfizer and Astellas Pharma's ADC Padcev plus MSD's PD-1 inhibitor Keytruda has offered significant improvements to EFS and OS over ...

Merck MRK announced that the FDA has accepted the two supplemental biologics license applications (sBLAs) seeking approval ...

Pfizer (PFE) and Astellas (ALPMF) (ALPMY) announced Monday that the FDA has granted priority review for their marketing application, which seeks U.S. approval for their antibody drug conjugate, Padcev ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for ...

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

The U.S. Food and Drug Administration (FDA) on Friday approved injectable and intravenous versions of Merck’s (MRK) blockbuster anti-PD-1 therapy Keytruda for bladder cancer as part of a combination ...

First and only systemic regimen to demonstrate durable survival benefit in this patient population KEYNOTE-905 marks the fifth study of a KEYTRUDA-based regimen in an earlier stage of cancer to ...

Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...